Business Standard

Biocon Q4 net up 75% at Rs 135 cr

Issues bonus shares in the ratio of 2:1

Biocon
Premium

Biocon

BS Reporter Bengaluru
Biocon, India’s largest biopharma firm, said its fourth quarter profits (before exceptional items) rose 75 per cent to Rs 135 crore and revenue growth was flat at Rs 974 crore. 

Bengaluru-based Biocon had reported profits of Rs 77 crore (before exceptional items) on revenue of Rs 973 crore in the corresponding quarter in FY16. It had seen a one-time gain of Rs 256 crore in profits as delayed revenue recognition for an insulin product in the period.

"Our Q4 revenue at Rs 974 crore reported a muted growth due to elongated approval timelines in some emerging markets, discontinuance of some

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in